The value of surgery in the patients with de novo stage Ⅳ breast cancer

doi:10.19401/j.cnki.1007-3639.2023.05.002

Abstract

Abstract:

Breast cancer is one of the common malignant tumors in the world. About 6% of the patients are de novo stage Ⅳ breast cancer, which is incurable. Traditionally, the role of surgery has been confined to relieving symptoms, improving quality of life and reducing tumor load. Nowadays, a multidisciplinary team is a prerequisite for optimal management, and patients with oligometastatic lesion always live for a long time. R0 resection of the primary and metastatic foci can extend the time of progression-free survival (PFS), which may bring survival benefits. Therefore, whether to perform surgery has become a hot clinical issue. This article deeply discussed extensively the surgical value in de novo stage Ⅳ breast cancer patients.

Key words: Stage Ⅳ breast cancer, Surgery, Multidisciplinary team, Oligometastatic lesion, Survival benefit

CLC Number:

R737.9

CHEN Luyan, WANG Lixue, FU Peifen. The value of surgery in the patients with de novo stage Ⅳ breast cancer[J]. China Oncology, 2023, 33(5): 431-436.

References 38

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.v71.3
[2]	GIAQUINTO A N, SUNG H, MILLER K D, et al. Breast cancer statistics, 2022[J]. CA A Cancer J Clin, 2022, 72(6): 524-541. doi: 10.3322/caac.v72.6
[3]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2015[J]. CA A Cancer J Clin, 2015, 65(1): 5-29. doi: 10.3322/caac.21254
[4]	ZHENG R S, ZHANG S W, ZENG H M, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Center, 2022, 2(1): 1-9. doi: 10.1016/j.jncc.2022.02.002
[5]	ARCIERO C, LIU Y, GILLESPIE T, et al. Surgery and survival in patients with stage Ⅳ breast cancer[J]. Breast J, 2019, 25(4): 644-653. doi: 10.1111/tbj.2019.25.issue-4
[6]	ZHENG A, GUO B L, ZHANG J G, et al. Clinical information and management status of de novo stage Ⅳ breast cancer patients: a Chinese multicenter investigation (CSBrS-002)[J]. Chin Med J (Engl), 2021, 134(13): 1569-1575.
[7]	MALINOWSKI C, LEI X D, ZHAO H, et al. Association of Medicaid expansion with mortality disparity by race and ethnicity among patients with de novo stage Ⅳ breast cancer[J]. JAMA Oncol, 2022, 8(6): 863-870. doi: 10.1001/jamaoncol.2022.0159
[8]	MALMGREN J A, MAYER M, ATWOOD M K, et al. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010[J]. Breast Cancer Res Treat, 2018, 167(2): 579-590. doi: 10.1007/s10549-017-4529-5
[9]	GRADISHAR W J, MORAN M S, ABRAHAM J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(6): 691-722. doi: 10.6004/jnccn.2022.0030
[10]	中华医学会外科学分会. 乳腺外科临床实践指南(2022版)[M]. 人民卫生出版社, 2022.
	Surgery Branch of Chinese Medical Association. Practice guidelines of Chinese society of breast surgery (2022)[M]. People’s Medical Publishing House, 2022.
[11]	GENNARI A, ANDRÉ F, BARRIOS C H, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer[J]. Ann Oncol, 2021, 32(12): 1475-1495. doi: 10.1016/j.annonc.2021.09.019 pmid: 34678411
[12]	SI Y R, YUAN P, HU N L, et al. Primary tumor surgery for patients with de novo stage Ⅳ breast cancer can decrease local symptoms and improve quality of life[J]. Ann Surg Oncol, 2020, 27(4): 1025-1033. doi: 10.1245/s10434-019-08092-2
[13]	YU Y F, HONG H M, WANG Y, et al. Clinical evidence for locoregional surgery of the primary tumor in patients with de novo stage Ⅳ breast cancer[J]. Ann Surg Oncol, 2021, 28(9): 5059-5070. doi: 10.1245/s10434-021-09650-3
[14]	KHAN S A, ZHAO F M, GOLDSTEIN L J, et al. Early local therapy for the primary site in de novo stage Ⅳ breast cancer: results of a randomized clinical trial (EA2108)[J]. J Clin Oncol, 2022, 40(9): 978-987. doi: 10.1200/JCO.21.02006
[15]	KHAN S A, STEWART A K, MORROW M. Does aggressive local therapy improve survival in metastatic breast cancer?[J]. Surgery, 2002, 132(4): 620-6;discussion626.
[16]	BABIERA G V, RAO R, FENG L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage Ⅳ disease and an intact primary tumor[J]. Ann Surg Oncol, 2006, 13(6): 776-782. doi: 10.1245/ASO.2006.03.033
[17]	RAPITI E, VERKOOIJEN H M, VLASTOS G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis[J]. J Clin Oncol, 2006, 24(18): 2743-2749. doi: 10.1200/JCO.2005.04.2226 pmid: 16702580
[18]	BAFFORD A C, BURSTEIN H J, BARKLEY C R, et al. Breast surgery in stage Ⅳ breast cancer: impact of staging and patient selection on overall survival[J]. Breast Cancer Res Treat, 2009, 115(1): 7-12. doi: 10.1007/s10549-008-0101-7
[19]	LANE W O, THOMAS S M, BLITZBLAU R C, et al. Surgical resection of the primary tumor in women with de novo stage Ⅳ breast cancer: contemporary practice patterns and survival analysis[J]. Ann Surg, 2019, 269(3): 537-544. doi: 10.1097/SLA.0000000000002621
[20]	SORAN A, OZMEN V, OZBAS S, et al. Primary surgery with systemic therapy in patients with de novo stage Ⅳ breast cancer: 10-year follow-up; protocol MF07-01 randomized clinical trial[J]. J Am Coll Surg, 2021, 233(6): 742-751.e5. doi: 10.1016/j.jamcollsurg.2021.08.686
[21]	BADWE R, PARMAR V, HAWALDAR R, et al. Abstract S2-02: surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: a randomized controlled trial[J]. Cancer Res, 2013, 73(24_Supplement): S2-2.
[22]	BADWE R, HAWALDAR R, NAIR N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial[J]. Lancet Oncol, 2015, 16(13): 1380-1388. doi: 10.1016/S1470-2045(15)00135-7 pmid: 26363985
[23]	KING T A, LYMAN J P, GONEN M, et al. Prognostic impact of 21-gene recurrence score in patients with stage Ⅳ breast cancer: TBCRC 013[J]. J Clin Oncol, 2016, 34(20): 2359-2365. doi: 10.1200/JCO.2015.63.1960
[24]	RAO R, FENG L, KUERER H M, et al. Timing of surgical intervention for the intact primary in stage Ⅳ breast cancer patients[J]. Ann Surg Oncol, 2008, 15(6): 1696-1702. doi: 10.1245/s10434-008-9830-4
[25]	ZHU S Y. Exploring the value of additional primary tumour excision combined with systemic therapy administered in different sequences for patients with de novo metastatic breast cancer[J]. Breast J, 2022, 2022: 5049445.
[26]	KOMMALAPATI A, TELLA S H, GOYAL G, et al. A prognostic scoring model for survival after locoregional therapy in de novo stage Ⅳ breast cancer[J]. Breast Cancer Res Treat, 2018, 170(3): 677-685. doi: 10.1007/s10549-018-4802-2
[27]	GERA R, CHEHADE H E L H, WAZIR U, et al. Locoregional therapy of the primary tumour in de novo stage Ⅳ breast cancer in 216 066 patients: a meta-analysis[J]. Sci Rep, 2020, 10(1): 2952. doi: 10.1038/s41598-020-59908-1
[28]	POCKAJ B A, WASIF N, DUECK A C, et al. Metastasectomy and surgical resection of the primary tumor in patients with stage Ⅳ breast cancer: time for a second look?[J]. Ann Surg Oncol, 2010, 17(9): 2419-2426. doi: 10.1245/s10434-010-1016-1
[29]	BILANI N, ELSON L, LIANG H, et al. Effect of surgery at primary and metastatic sites in patients with stage Ⅳ breast cancer[J]. Clin Breast Cancer, 2021, 21(3): 170-180. doi: 10.1016/j.clbc.2020.08.008
[30]	BILANI N, YAGHI M, SINGH JABBAL I, et al. Survival benefit of a combined surgical approach in patients with metastatic breast cancer[J]. J Surg Oncol, 2021, 124(8): 1235-1241. doi: 10.1002/jso.v124.8
[31]	HELLMAN S, WEICHSELBAUM R R. Oligometastases[J]. J Clin Oncol, 1995, 13(1): 8-10. doi: 10.1200/JCO.1995.13.1.8 pmid: 7799047
[32]	CARDOSO F, PALUCH-SHIMON S, SENKUS E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)[J]. Ann Oncol, 2020, 31(12): 1623-1649. doi: 10.1016/j.annonc.2020.09.010
[33]	LACAZE J L, AZIZA R, CHIRA C, et al. Diagnosis, biology and epidemiology of oligometastatic breast cancer[J]. Breast, 2021, 59: 144-156. doi: 10.1016/j.breast.2021.06.010
[34]	BILANI N, YAGHI M, MAIN O, et al. Metastasectomy versus radiation of secondary sites in stage Ⅳ breast cancer: analysis from a national cancer registry[J]. Breast, 2021, 60: 185-191. doi: 10.1016/j.breast.2021.10.005
[35]	IMOTO S, WANG K, BI X W, et al. Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)[J]. Breast Cancer, 2023, 30(3): 412-423. doi: 10.1007/s12282-023-01436-7 pmid: 36689066
[36]	SADOT E, LEE S Y, SOFOCLEOUS C T, et al. Hepatic resection or ablation for isolated breast cancer liver metastasis: a case-control study with comparison to medically treated patients[J]. Ann Surg, 2016, 264(1): 147-154. doi: 10.1097/SLA.0000000000001371 pmid: 26445472
[37]	CHMURA S J, WINTER K A, WOODWARD W A, et al. NRG-BR002: a phase ⅡR/Ⅲ trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)[J]. J Clin Oncol, 2022, 40: 1007. doi: 10.1200/JCO.2022.40.16_suppl.1007
[38]	ZHENG C, YU Z G, CHINESE SOCIETY OF BREAST SURGERY. Clinical practice guidelines for pre-operative evaluation of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021[J]. Chin Med J (Engl), 2021, 134(18): 2147-2149.